CLINICAL CASE: USE OF CANAKINUMAB IN A PATIENT WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS RESISTANT TO IMMUNOSUPPRESSANTS AND GENETICALLY ENGINEERED BIOPHARMACEUTICALS
The article presents a case of successful use of an interleukin-1 monoclonal antibody drug (canakinumab) for severe systemic juvenile idiopathic arthritis refractory to treatment with classic immunosuppressants and genetically engineered biopharmaceuticals with a different mode of action. Canakinuma...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Union of pediatricians of Russia
2014-03-01
|
| Series: | Педиатрическая фармакология |
| Subjects: | |
| Online Access: | https://www.pedpharma.ru/jour/article/view/127 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849404756783529984 |
|---|---|
| author | E. I. Alexeeva R. V. Denisova T. V. Sleptsova T. M. Bzarova K. B. Isaeva E. V. Mitenko E. G. Chistyakova A. M. Chomakhidze N. I. Taybulatov A. N. Fetisova O. L. Lomakina S. I. Valieva |
| author_facet | E. I. Alexeeva R. V. Denisova T. V. Sleptsova T. M. Bzarova K. B. Isaeva E. V. Mitenko E. G. Chistyakova A. M. Chomakhidze N. I. Taybulatov A. N. Fetisova O. L. Lomakina S. I. Valieva |
| author_sort | E. I. Alexeeva |
| collection | DOAJ |
| description | The article presents a case of successful use of an interleukin-1 monoclonal antibody drug (canakinumab) for severe systemic juvenile idiopathic arthritis refractory to treatment with classic immunosuppressants and genetically engineered biopharmaceuticals with a different mode of action. Canakinumab treatment shortly provided reduction in clinical and laboratory parameters of the disease activity, life quality improvement, development of an inactive disease stage and allowed reducing the prednisolone dose by 90% and avoiding intravenous and intraarticular administration of glucocorticoids. |
| format | Article |
| id | doaj-art-74f2cdba75ec4660a374045f500a0598 |
| institution | Kabale University |
| issn | 1727-5776 2500-3089 |
| language | Russian |
| publishDate | 2014-03-01 |
| publisher | Union of pediatricians of Russia |
| record_format | Article |
| series | Педиатрическая фармакология |
| spelling | doaj-art-74f2cdba75ec4660a374045f500a05982025-08-20T03:36:53ZrusUnion of pediatricians of RussiaПедиатрическая фармакология1727-57762500-30892014-03-01112889410.15690/pf.v11i2.965127CLINICAL CASE: USE OF CANAKINUMAB IN A PATIENT WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS RESISTANT TO IMMUNOSUPPRESSANTS AND GENETICALLY ENGINEERED BIOPHARMACEUTICALSE. I. Alexeeva0R. V. Denisova1T. V. Sleptsova2T. M. Bzarova3K. B. Isaeva4E. V. Mitenko5E. G. Chistyakova6A. M. Chomakhidze7N. I. Taybulatov8A. N. Fetisova9O. L. Lomakina10S. I. Valieva11Scientific Center of Children’s Health, Moscow Sechenov First Moscow State Medical UniversityScientific Center of Children’s Health, Moscow, Russian FederationScientific Center of Children’s Health, Moscow, Russian FederationScientific Center of Children’s Health, Moscow, Russian FederationScientific Center of Children’s Health, Moscow, Russian FederationScientific Center of Children’s Health, Moscow, Russian FederationScientific Center of Children’s Health, Moscow, Russian Federation Sechenov First Moscow State Medical University, Russian FederationScientific Center of Children’s Health, Moscow, Russian FederationScientific Center of Children’s Health, Moscow, Russian FederationScientific Center of Children’s Health, Moscow, Russian FederationScientific Center of Children’s Health, Moscow, Russian FederationScientific Center of Children’s Health, Moscow, Russian FederationThe article presents a case of successful use of an interleukin-1 monoclonal antibody drug (canakinumab) for severe systemic juvenile idiopathic arthritis refractory to treatment with classic immunosuppressants and genetically engineered biopharmaceuticals with a different mode of action. Canakinumab treatment shortly provided reduction in clinical and laboratory parameters of the disease activity, life quality improvement, development of an inactive disease stage and allowed reducing the prednisolone dose by 90% and avoiding intravenous and intraarticular administration of glucocorticoids.https://www.pedpharma.ru/jour/article/view/127systemic juvenile idiopathic arthritiscanakinumabchildren |
| spellingShingle | E. I. Alexeeva R. V. Denisova T. V. Sleptsova T. M. Bzarova K. B. Isaeva E. V. Mitenko E. G. Chistyakova A. M. Chomakhidze N. I. Taybulatov A. N. Fetisova O. L. Lomakina S. I. Valieva CLINICAL CASE: USE OF CANAKINUMAB IN A PATIENT WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS RESISTANT TO IMMUNOSUPPRESSANTS AND GENETICALLY ENGINEERED BIOPHARMACEUTICALS Педиатрическая фармакология systemic juvenile idiopathic arthritis canakinumab children |
| title | CLINICAL CASE: USE OF CANAKINUMAB IN A PATIENT WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS RESISTANT TO IMMUNOSUPPRESSANTS AND GENETICALLY ENGINEERED BIOPHARMACEUTICALS |
| title_full | CLINICAL CASE: USE OF CANAKINUMAB IN A PATIENT WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS RESISTANT TO IMMUNOSUPPRESSANTS AND GENETICALLY ENGINEERED BIOPHARMACEUTICALS |
| title_fullStr | CLINICAL CASE: USE OF CANAKINUMAB IN A PATIENT WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS RESISTANT TO IMMUNOSUPPRESSANTS AND GENETICALLY ENGINEERED BIOPHARMACEUTICALS |
| title_full_unstemmed | CLINICAL CASE: USE OF CANAKINUMAB IN A PATIENT WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS RESISTANT TO IMMUNOSUPPRESSANTS AND GENETICALLY ENGINEERED BIOPHARMACEUTICALS |
| title_short | CLINICAL CASE: USE OF CANAKINUMAB IN A PATIENT WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS RESISTANT TO IMMUNOSUPPRESSANTS AND GENETICALLY ENGINEERED BIOPHARMACEUTICALS |
| title_sort | clinical case use of canakinumab in a patient with systemic juvenile idiopathic arthritis resistant to immunosuppressants and genetically engineered biopharmaceuticals |
| topic | systemic juvenile idiopathic arthritis canakinumab children |
| url | https://www.pedpharma.ru/jour/article/view/127 |
| work_keys_str_mv | AT eialexeeva clinicalcaseuseofcanakinumabinapatientwithsystemicjuvenileidiopathicarthritisresistanttoimmunosuppressantsandgeneticallyengineeredbiopharmaceuticals AT rvdenisova clinicalcaseuseofcanakinumabinapatientwithsystemicjuvenileidiopathicarthritisresistanttoimmunosuppressantsandgeneticallyengineeredbiopharmaceuticals AT tvsleptsova clinicalcaseuseofcanakinumabinapatientwithsystemicjuvenileidiopathicarthritisresistanttoimmunosuppressantsandgeneticallyengineeredbiopharmaceuticals AT tmbzarova clinicalcaseuseofcanakinumabinapatientwithsystemicjuvenileidiopathicarthritisresistanttoimmunosuppressantsandgeneticallyengineeredbiopharmaceuticals AT kbisaeva clinicalcaseuseofcanakinumabinapatientwithsystemicjuvenileidiopathicarthritisresistanttoimmunosuppressantsandgeneticallyengineeredbiopharmaceuticals AT evmitenko clinicalcaseuseofcanakinumabinapatientwithsystemicjuvenileidiopathicarthritisresistanttoimmunosuppressantsandgeneticallyengineeredbiopharmaceuticals AT egchistyakova clinicalcaseuseofcanakinumabinapatientwithsystemicjuvenileidiopathicarthritisresistanttoimmunosuppressantsandgeneticallyengineeredbiopharmaceuticals AT amchomakhidze clinicalcaseuseofcanakinumabinapatientwithsystemicjuvenileidiopathicarthritisresistanttoimmunosuppressantsandgeneticallyengineeredbiopharmaceuticals AT nitaybulatov clinicalcaseuseofcanakinumabinapatientwithsystemicjuvenileidiopathicarthritisresistanttoimmunosuppressantsandgeneticallyengineeredbiopharmaceuticals AT anfetisova clinicalcaseuseofcanakinumabinapatientwithsystemicjuvenileidiopathicarthritisresistanttoimmunosuppressantsandgeneticallyengineeredbiopharmaceuticals AT ollomakina clinicalcaseuseofcanakinumabinapatientwithsystemicjuvenileidiopathicarthritisresistanttoimmunosuppressantsandgeneticallyengineeredbiopharmaceuticals AT sivalieva clinicalcaseuseofcanakinumabinapatientwithsystemicjuvenileidiopathicarthritisresistanttoimmunosuppressantsandgeneticallyengineeredbiopharmaceuticals |